zurück Home

Sinonasale Tumoren

allgemeines Tumoren der Nasenhöhle und der Nasennebenhöhlen

Epidemiologie

Ziemlich selten, 3-5% der HNO-Tumoren

Prognose

 

Klinik

Lange asymptomatisch. Diagnose oft schwierig.
Bezirke C30.0 Nasenhöhle Septum
Nasenboden
laterale Wand
Vestibulum
C31.0 Kieferhöhle  
C31.1 Siebbeinzellen  

Metastasierung

 

Staging

TNM-Klassifikation. T1und T2 unterschiedlich bei Kieferhöhlentumoren und Nasenhöhlentumoren, T4 , N-und M - Stadien gleich.

Diagnostik

Tumor der Nasenhaupthöhle mit Zerstörung des Nasenseptums uns Infiltration der Nasenhaut.

Morphologie

Sonderform: invertierte Papillome

Therapie

Kombination von Operation und Strahlentherapie

Operation

 

Radiatio

 

Chemotherapie

 

offene Protokolle

 

Ergebnisse

 

Rest

Sinonasales Teratokarzinom, -Karzinosarkom J Laryngol Otol. 2010 Jul;124(7):739-43. Epub 2010 Feb 16. Management and clinical outcome of sinonasal teratocarcinosarcoma: single institution experience. Budrukkar A, Agarwal JP, Kane S, Siddha M, Laskar SG, Pai P, Murthy V, Sengar M, D'Cruz A. SourceDepartment of Radiation Oncology, Tata Memorial Hospital, Parel, Mumbai, India. Abstract PURPOSE: To study the outcome of patients with sinonasal teratocarcinosarcoma treated at a single institution. METHODS: We reviewed the medical records of 22 patients with histopathologically proven sinonasal teratocarcinosarcoma diagnosed during the period 1993-2007. Treatment was completed in 16 patients. RESULTS: Fourteen patients underwent surgery (six received craniofacial resection, four open surgery and four endoscopic resection); this was followed by radiation therapy with or without chemotherapy in 11 patients. Two patients received chemoradiation as the definitive treatment. At median follow up in surviving patients of 34 months (range one to 180 months), only five were controlled. Disease recurred in 11 patients, with a median time to recurrence of seven months. The two-year disease-free survival rate and the overall survival rate were 28 and 46 per cent, respectively. CONCLUSION: Sinonasal teratocarcinosarcoma appears to be an aggressive disease, with the majority of patients suffering locoregional failure. Multimodality treatment, in the form of a combination of surgery, radiation therapy and chemotherapy, appears to be the optimal approach. Arch Otolaryngol Head Neck Surg. 2008 Jun;134(6):592-5. Sinonasal teratocarcinosarcoma of the head and neck: a report of 10 patients treated at a single institution and comparison with reported series. Smith SL, Hessel AC, Luna MA, Malpica A, Rosenthal DI, El-Naggar AK. SourceDepartment of Head and Neck Surgery, The University of Texas Medical School, Houston, TX, USA. Abstract OBJECTIVES: To present the clinicopathologic features of 10 sinonasal teratocarcinosarcomas managed at a single center. Teratocarcinosarcoma is a rare morphologically heterogeneous and highly malignant neoplasm. Previous reports of these tumors have focused on their differential diagnosis and histogenesis and consisted of individual case reports and consultation based series. DESIGN: Review of patient medical records and microscopic slides of all tumor tissues. The histopathologic features for each tumor and the demographic, clinical, treatment, and follow-up information were recorded for each patient. Also, a comparison with previously reported series was performed. SETTING: The University of Texas M. D. Anderson Cancer Center. PATIENTS: Ten men ranging in age from 35 to 69 years (mean age, 53 years) were included in the study. They all experienced a short course of symptoms, with an average duration of 3.5 months, and 9 presented with nasal obstruction and epistaxis. Nine patients were treated with both surgery and irradiation. RESULTS: Histologically, the tumors showed primitive neuroepithelial elements and various malignant epithelial and mesenchymal components. Six patients had no evidence of disease by the end of follow-up, which ranged from 72 to 372 months. Three patients died of disease, and 1 patient was lost to follow-up. CONCLUSION: Sinonasal teratocarcinosarcoma of the head and neck is a histologically and biologically heterogeneous malignant neoplasm that is best managed with surgery and postoperative radiotherapy.
blauer Punkt

Impressum .....................................................................................Zuletzt geändert am 28.05.2013 11:59